MALT1 and B-cell chronic lymphocytic leukemia: The first clinical trials using the MALT1 inhibitor JNJ-67856633 are currently ongoing in patients with non-Hodgkin’s Lymphoma and CLL (Clinical trials.gov; NCT03900598 and NCT04876092).